Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

EET Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide Orion’s collaboration partner Bayer has submitted an application to the Center of Drug ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Overall, PSMA-PET/CT detected distant metastasis in 84 of 182 cases (46%) that were negative by other types of imaging, ...

New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) frequently detects metastatic disease missed by conventional imaging, investigators report.

Nearly half of high-risk prostate cancer patients classified as nonmetastatic by traditional imaging show metastases when ...

Advanced imaging reveals hidden metastases in high-risk prostate cancer cases, offering new insights for better diagnosis and treatment strategies.

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...